Next Article in Journal
Probiotic Ferulic Acid Esterase Active Lactobacillus fermentum NCIMB 5221 APA Microcapsules for Oral Delivery: Preparation and in Vitro Characterization
Next Article in Special Issue
Heterocycles in Peptidomimetics and Pseudopeptides: Design and Synthesis
Previous Article in Journal
Effects of Scrophularia ningpoensis Hemsl. on Inhibition of Proliferation, Apoptosis Induction and NF-κB Signaling of Immortalized and Cancer Cell Lines
Previous Article in Special Issue
RFamide Peptides: Structure, Function, Mechanisms and Pharmaceutical Potential
Open AccessReview

Structure Based Antibody-Like Peptidomimetics

Department of Biomedical Sciences, Cedars-Sinai Medical Center, D5091 Davis Building, 8700 Beverly Blvd., Los Angeles, CA 90048, USA
Department of Pathology and Laboratory of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
Authors to whom correspondence should be addressed.
Pharmaceuticals 2012, 5(2), 209-235;
Received: 16 December 2011 / Revised: 17 January 2012 / Accepted: 19 January 2012 / Published: 16 February 2012
(This article belongs to the Special Issue Peptidomimetics)
Biologics such as monoclonal antibodies (mAb) and soluble receptors represent new classes of therapeutic agents for treatment of several diseases. High affinity and high specificity biologics can be utilized for variety of clinical purposes. Monoclonal antibodies have been used as diagnostic agents when coupled with radionuclide, immune modulatory agents or in the treatment of cancers. Among other limitations of using large molecules for therapy the actual cost of biologics has become an issue. There is an effort among chemists and biologists to reduce the size of biologics which includes monoclonal antibodies and receptors without a reduction of biological efficacy. Single chain antibody, camel antibodies, Fv fragments are examples of this type of deconstructive process. Small high-affinity peptides have been identified using phage screening. Our laboratory used a structure-based approach to develop small-size peptidomimetics from the three-dimensional structure of proteins with immunoglobulin folds as exemplified by CD4 and antibodies. Peptides derived either from the receptor or their cognate ligand mimics the functions of the parental macromolecule. These constrained peptides not only provide a platform for developing small molecule drugs, but also provide insight into the atomic features of protein-protein interactions. A general overview of the reduction of monoclonal antibodies to small exocyclic peptide and its prospects as a useful diagnostic and as a drug in the treatment of cancer are discussed. View Full-Text
Keywords: antibody; CDR; peptidomimetics; Her2; Herceptin; drug-delivery; therapeutics; tumor imaging; AHNP; AERP antibody; CDR; peptidomimetics; Her2; Herceptin; drug-delivery; therapeutics; tumor imaging; AHNP; AERP
Show Figures

Figure 1

MDPI and ACS Style

Murali, R.; Greene, M.I. Structure Based Antibody-Like Peptidomimetics. Pharmaceuticals 2012, 5, 209-235.

Show more citation formats Show less citations formats

Article Access Map by Country/Region

Only visits after 24 November 2015 are recorded.
Back to TopTop